新基医药

CELG NASDAQ
95.68
0.00
0.00%
交易中 10:16 08/22 EDT
开盘
95.75
昨收
95.68
最高
95.99
最低
95.56
成交量
18.89万
成交均量(3M)
413.31万
52周最高
98.97
52周最低
58.59
换手率
0.03%
市值
678.16亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供新基医药 CELG股票价格,新基医药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
展开 >

最近浏览

名称
价格
涨跌幅